Sunny Pharmtech Announces Strategic Collaboration with Company D for Lymphoma Drug Development
On August 27, Sunny Pharmtech announced a strategic collaboration with Company D to develop a drug targeting Lymphoma. The partnership will initially focus on the U.S. market, with plans to gradually expand into global markets. Sunny and Company D have previously collaborated on products sold in the U.S., and this new agreement marks a further deepening of their cooperation, aiming to provide patients in the U.S. and worldwide with a stable, high-quality, and scalable supply of essential medicines.
Romidepsin Injection is developed using in-house technology. Following the signing of the agreement, Sunny is expected to receive upfront payments and milestone-based payments based on development progress. Once the product is launched, both parties will collaborate on marketing efforts and share subsequent revenue.